share_log

Guggenheim Initiates Coverage On Aerovate Therapeutics With Buy Rating, Announces Price Target of $36

Benzinga ·  Mar 1, 2023 05:27

Guggenheim analyst Vamil Divan initiates coverage on Aerovate Therapeutics (NASDAQ:AVTE) with a Buy rating and announces Price Target of $36.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment